Endometriosis News and Research

Latest Endometriosis News and Research

The AFA and IntegraMed partner to provide innovative fertility education programs

Patients dealing with infertility face many uncertainties, but now there is one place to find a comprehensive guide to almost every aspect of infertility treatment.

19 Apr 2010

StockPreacher.com releases investment report on Repros Therapeutics

StockPreacher.com announces an investment report featuring Repros Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

Request for lift of full clinical hold on Proellex program

Repros Therapeutics Inc. today announced that the Company has requested a lift of the full clinical hold on its oral drug Proellex® being developed for the treatment of uterine fibroids and endometriosis. On August 4, 2009, the FDA noted that further testing of Proellex® was placed on full clinical hold due to findings of serious adverse events associated with liver toxicity.

5 Apr 2010

Soligenix's revenues for 2009 increase by 22%

Soligenix, Inc., a late-stage biopharmaceutical company, today announced its financial results for 2009.

1 Apr 2010

Facts and treatment options for endometriosis

One out of every two women struggling to conceive may suffer from endometriosis - the leading cause of infertility - according to research from Camran Nezhat, M.D., gynecologist at El Camino Hospital, the hospital of the Silicon Valley.

31 Mar 2010

Painful periods at early age doubles risk of endometriosis

Queensland Institute of Medical Research scientists have identified a new link between strong period pain experienced in adolescence and early adulthood and the risk of endometriosis.

15 Mar 2010

Neurocrine Biosciences to sell common stock shares

Neurocrine Biosciences, Inc. today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is the sole book-running manager for this offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

5 Mar 2010

Soligenix' LPM oral drug delivery technology receives Hong Kong patent

Soligenix, Inc., a late-stage biotechnology company, announced today that it has received a Hong Kong patent which addresses its Lipid Polymer Micelle (LPM™) technology for the improved oral delivery of drugs. The issued Hong Kong patent, HK 1071054, entitled "Stabilized Reverse Micelle Compositions and Uses Thereof" covers lipid structures (reverse micelles) that promote the intestinal absorption of peptides and other sensitive drugs that cannot otherwise be given orally.

17 Feb 2010

Clinical research study conducted for patients with IC/PBS

A clinical research study is being conducted for patients with Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS), a chronic bladder disorder characterized by intense pelvic pain, urinary frequency-urgency, and pain during sexual intimacy (www.PainfulBladderStudy.org). It is estimated that as many as 1.3 million people in the U.S. have been diagnosed with this disease and many more remain undiagnosed.

12 Feb 2010

Ipsen launches Decapeptyl LP 22.5 mg in France

Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.

4 Feb 2010

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

Soligenix, Inc., a late-stage biotechnology company, announced today the publication of an article in the February 2010 edition of Vaccine, which describes preclinical formulations of RiVax™, its ricin toxin vaccine, with heightened stability. The article was authored by the Company's collaborators at the University of Texas Southwestern Medical Center at Dallas (UT Southwestern) where the vaccine originated. RiVax™ is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as non-human primate trials for efficacy.

3 Feb 2010

Merck receives marketing authorization for ELONVA

Merck & Co., Inc., which operates outside the U.S. and Canada as MSD, today announced the European Commission (EC) approval of ELONVA® (corifollitropin alfa injection). ELONVA is indicated for controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (ART) program.

28 Jan 2010

Infertility can lead to isolation and impact on couple’s relationships

Struggling to get pregnant can be a serious blow to the self-esteem of both women and men, according to a new national survey. Seven in 10 (71 percent) women said that infertility makes them feel flawed, while half of men (50 percent) say it makes them feel inadequate.

22 Jan 2010

Findings suggest abuse is a risk factor for chronic headache

Researchers from the American Headache Society's Women's Issues Section Research Consortium found that incidence of childhood maltreatment, especially emotional abuse and neglect, are prevalent in migraine patients.

5 Jan 2010

Cryo-Cell International continues to expand R&D initiatives to accelerate therapeutic benefits of stem cells

Cryo-Cell International, Inc. a global leader in stem cell innovation, resolves to help women inspire and empower each other to take charge of their health in the New Year, and to spark conversations about the promise of stem cells.

31 Dec 2009

Promising results from Soligenix' RiVax vaccine against ricin toxin

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today the publication of an article in the January 2010 edition of Infection and Immunity, detailing the characteristics of several immunodominant regions of ricin A chain, the antigenic component of RiVax((TM)). RiVax((TM)) is Soligenix's vaccine to protect against exposure to ricin toxin and is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as nonhuman primate trials for efficacy.

29 Dec 2009

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Neurocrine Biosciences, Inc. today announced their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-98854, will be advanced in clinical development.

21 Dec 2009

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

21 Dec 2009

Neurocrine Biosciences to sell 4,784,689 shares of common stock to Venrock affiliates

Neurocrine Biosciences, Inc. today reported that it has entered into a privately negotiated transaction to sell an aggregate of 4,784,689 primary shares of its common stock to affiliates of Venrock at a price of $2.09 per share, raising aggregate gross proceeds to Neurocrine of approximately $10 million. Neurocrine expects the financing to close on or about December 22, 2009, subject to customary closing conditions.

17 Dec 2009

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from the Tulip PETAL Study (703 Study), its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

10 Dec 2009